HUMALOG MIX75/25 Dosage & Rx Info

Humalog Mix75/25 Generic Name & Formulations

Legal Class

General Description

Insulin lispro protamine suspension 75% (rDNA origin), insulin lispro 25% (rDNA origin) 100 Units/mL; SC inj; contains zinc, m-cresol.

How Supplied

Humalog Mix75/25, Humalog Mix50/50, Humalog vials (10mL)—1; Humalog Mix, Humalog U-100 KwikPen (prefilled) (3mL), Humalog U-100 Tempo Pen (prefilled) (3mL), Humalog U-100 Junior KwikPen (prefilled) (3mL), Humalog U-200 KwikPen (prefilled) (3mL)—5; Humalog cartridges (3mL)—5; HumaPen LUXURA HD (inj device, uses Humalog cartridges)—1

Manufacturer

Eli Lilly and Company

Mechanism of Action

The primary activity of insulin is the regulation of glucose metabolism. In addition, all insulins have several anabolic and anti-catabolic actions on many tissues in the body. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly, promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat. Insulin lispro, the rapid-acting component of Humalog Mix75/25, has been shown to be equipotent to Regular human insulin on a molar basis.

Humalog Mix75/25 Indications

Indications

Diabetes.

Humalog Mix75/25 Dosage and Administration

Adult

≥18yrs: SC inj only. Onset approx ≤15mins, peak 1–6hrs, duration 13–22hrs.

Children

<18yrs: not established.

Humalog Mix75/25 Contraindications

Contraindications

During episodes of hypoglycemia.

Humalog Mix75/25 Boxed Warnings

Not Applicable

Humalog Mix75/25 Warnings/Precautions

Warnings/Precautions

Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, cartridges, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyperglycemia of hypoglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K⁺-lowering or K⁺-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Pregnancy. Nursing mothers.

Humalog Mix75/25 Pharmacokinetics

Absorption

Median peak serum concentration: 60 minutes (range: 30 minutes to 4 hours) after dosing.

Metabolism

Hepatic.

Humalog Mix75/25 Interactions

Interactions

Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. When mixing insulin lispro with other insulins, draw insulin lispro into syringe first and inject mixture immediately.

Humalog Mix75/25 Adverse Reactions

Adverse Reactions

Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.

Humalog Mix75/25 Clinical Trials

See Literature

Humalog Mix75/25 Note